Trial summary
A Phase 2 study to evaluate the efficacy and safety of azenossertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Azenosertib is a selective and orally bioavailable inhibitor of WEE1. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage leading to mitotic catastrophe and cancer cell death.
The study consists of two parts:
Part 1: All comers, no biomarker status required (completed enrollment).
Part 2: Cyclin E1 positive protein expression required.
Trial details
Short title
ZN-c3-005
Diagnosis
Ovarian cancer
Type of treatment
Medical Oncology
Phase
II
Locations
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.